Clinical Trials · NCT05370235
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Clinuvel Europe Limited
- Enrollment
- 6
- Start date
- Mar 2022
- Locations
- 2 sites, Belgium, Spain
- Primary endpoint
- Change in minimal erythema dose (MED) in patients with XP-C.